BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Por Rossi, Adriana, Mark, Tomer, Jayabalan, David, Christos, Paul, Zafar, Faiza, Pekle, Karen, Pearse, Roger, Chen-Kiang, Selina, Coleman, Morton, Niesvizky, Ruben
Publicado em 2013

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

Por Mark, Tomer, Stern, Jessica, Furst, Jessica R., Jayabalan, David, Zafar, Faiza, LaRow, April, Pearse, Roger N., Harpel, John, Shore, Tsiporah, Schuster, Michael W., Leonard, John P., Christos, Paul J., Coleman, Morton, Niesvizky, Ruben
Publicado em 2008

Overcoming the response plateau in multiple myeloma: A novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization

Por Niesvizky, Ruben, Mark, Tomer M., Ward, Maureen, Jayabalan, David S., Pearse, Roger N., Manco, Megan, Stern, Jessica, Christos, Paul J., Mathews, Lena, Shore, Tsiporah B., Zafar, Faiza, Pekle, Karen, Xiang, Zhaoying, Ely, Scott, Skerret, Donna, Chen-Kiang, Selina, Coleman, Morton, Lane, Maureen E.
Publicado em 2013